Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Three Champions League teams advance, with no boost for fan tokens

Three Champions League teams advance, with no boost for fan tokens

金色财经金色财经2025/04/23 22:26
Show original

Jinse reports that Paris Saint-Germain (PSG / $PSG), FC Barcelona ($BAR), and Inter Milan ($INTER) progressed to the Champions League semi-finals, but their official crypto fan tokens did not see significant increases. Since advancing on April 15, $PSG and $BAR have only risen by 0.5% and 0.6%, while $INTER, which progressed the following day, actually fell by 1%. The article notes that these slight price movements are "largely inconsequential" due to the "extremely low trading liquidity" of fan tokens. Analysts suggest that these tokens are more akin to "brand loyalty points" rather than assets with investment value.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Yen appreciation and global bond slump lead Japan GPIF to first loss in six quarters, with almost no asset allocation adjustment

According to the latest quarterly report from Japan’s Government Pension Investment Fund (GPIF), its asset allocation remained almost unchanged from its model portfolio for the three months ending in late September. However, the fund recorded a 1.7% quarterly loss during this period—the first loss in six quarters—due to a global slump in bond prices and the appreciation of the yen.

智通财经•2026/11/06 08:27

GlaxoSmithKline endorses: anti-inflammatory biotech company Rezera (RZRA.US) plans to raise $200 millions through IPO, with a valuation of $254 millions

Rezera plans to raise $200 million in its IPO on Nasdaq, with an offering price between $11 and $13. GSK intends to subscribe for up to $25 million. The mid-point valuation is $254 million, and the company focuses on oral NLRP3 inhibitors.

智通财经•2026/11/06 07:56